Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Gynecologic 4

Conditions

Multiple Myeloma 43Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 12Sarcoma 8Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Lymphoma 5Glioblastoma 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, Non-Hodgkin 4Endometrial Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

Paclitaxel 95Carboplatin 76pembrolizumab 72Cisplatin 28Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × selinexor × Clear all
NCT05611931 2026-04-23

XPORT-EC-042

Karyopharm Therapeutics Inc

Phase 3 Recruiting
276 enrolled
Gynecologic

Endometrial Neoplasms

NCT03555422 2026-04-13

ENGOT-EN5

Karyopharm Therapeutics Inc

Phase 3 Completed
263 enrolled
Gynecologic

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT02025985 2023-01-26

SIGN

Karyopharm Therapeutics Inc

Phase 2 Completed
116 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
23 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡